Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLT012 in Advanced Solid Tumors
NCT07337525Phase 1Recruiting
- Sponsor
- Pilatus Biosciences
- Start
- Feb 2026
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PLT012 in solid tumor, sponsored by Pilatus Biosciences. Primary endpoint: Dose Limiting Toxicities and Adverse Events at 18 months. Started Feb 2026; status: recruiting.
02
Drugs
PLT012
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07337525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07337525.